Rapid Screening of Volatile Ion-Pair Reagents Using UHPLC and Robust Analytical Method Development Using DoE for an Acetyl Cholinesterase Inhibitor: Galantamine HBr

Abstract

As over 70% of pharmaceutical compounds are bases, the analysis of these basic compounds by high performance liquid chromatography (HPLC) continues to be of great value and interesting. Acetyl cholinesterase inhibitors (AChEIs), which contain the basic compounds like Rivastigmine tartrate, Galantamine hydrobromide and Donepezil with different polarities, were chosen for the study. A rapid screening of the volatile ion-pairing reagents was performed using modern techniques like ultra high performance liquid chromatography (UHPLC). The experiments were planned using the 'Design of Experiments' (DoE) approach to identify the LC-MS compatible ion-pair reagent. In this study, Heptafluorobutyric acid (HFBA) has given a very good peak shape with tailing factor at 1.4 and theoretical plates up to *5,000 were observed, compared to tailing factor at 1.9 and theoretical plates up to *3,000 with non-volatile ion-pair reagent sodium heptane sulphonate (SHS). Similarly retention with HFBA was optimum as *5 min in short run time method compared to *13 min with SHS. This ion-pair reagent has proved to be good replacement of sodium alkyl sulphonate modifiers. HFBA can also be used for semi-preparative work for isolation of impurities by just evaporating the solvents. It avoids the extraction of other inorganic modifiers.Keywords Ultra high performance liquid chromatography (UHPLC) Á Volatile ion-pair reagents Á Design of experiments (DoE) Á Acetylcholinesterase inhibitor (AChEI) Á Alzheimer's disease (AD)

Quality by Design in Action 1: Controlling Critical Quality Attributes of an Active Pharmaceutical Ingredient

“…The 2 3 full factorial design and the results of same are captured in Table 5. It is clear from the results that except for the yield, all a A 2 3 full factorial design with four center points was planned to study the effect of the three important input PP 5 on the CQAs with all of the other PPs kept at predefined levels.…”

“…Nowadays, Quality by Design (QbD) has become an essential part of any process development pertaining to drug substances, 1,2 drug products, and analytical method development. 3 QbD is based on Juran's concept of "planning quality into the product" 4 at the design stage itself, rather than "complying product to the quality or Quality by QC". Designing quality into the product can be achieved only by having a proper understanding of the relationship between the critical quality attributes (CQAs) and the critical process parameters (CPPs) and critical material attributes (CMAs), as shown in Figures 1 and 2.…”

“…Nowadays, Quality by Design (QbD) has become an essential part of any process development pertaining to drug substances, , drug products, and analytical method development . QbD is based on Juran’s concept of “planning quality into the product” at the design stage itself, rather than “complying product to the quality or Quality by QC”.…”

Analytical Quality-By-Design Compliant Ultrafast Liquid Chromatographic Method for Determination of Paliperidone in Extended Release Tablet Dosage Form

“…The design space is an experimental safe zone where the method variables have no significant influence on the quality of product. Response surface methods like Factorial Design (FD), Fractional Factorial Design (FFD), Central Composite Design (CCD) and Box-Behnken Design (BBD) are used for predicting and optimizing the responses for most of the analytical techniques [25][26][27][28]. These designs help the analytical scientists to understand the relationship between different method variables and their effect on the responses produced.…”

Applications of Gage Reproducibility & Repeatability (GRR): Understanding and Quantifying the Effect of Variations from Different Sources on a Robust Process Development

“…Nowadays, quality by design (QbD) is an essential part of any process development activity. This is evident by the fact that there is a plethora of literature available on the QbD approach for the process development of drug substance, drug product, and analytical method development . These research articles focus on the process development of drug substances and drug products assuming that the measurement systems (MS) are perfect for the intended test, and even if they are not, it has rarely been discussed in these articles with some exceptions. , The real outcome of any process consists of measurable attributes such as critical quality attributes (CQA) associated with the product, for example, assay, purity, impurity levels, pH, and so forth, and in order to measure these attributes one requires some kind of MS such as high-pressure liquid chromatography (HPLC), gas chromatography (GC), and so forth.…”